Skip to content

Randomized study on evaluating microfluidic devices using sperms for clinical sample

Randomized study on evaluating microfluidic devices using sperms for clinical sample - Evaluation of microfluidic devices using sperms for clinical sample

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000013452
Enrollment
120
Registered
2014-03-18
Start date
2014-04-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Male infertility

Interventions

(1)Taking pictures of paper-based devices after semen application (2)Evaluation for in vitro fertilization using micro-beads as model of embryos Male fertility case Male infertility case

Sponsors

IRB in Okayama University
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: Sperms of patients in assisted reproductive center of Miyake Clinic

Exclusion criteria

Exclusion criteria: No standard

Design outcomes

Primary

MeasureTime frame
(1) Paper-based device: The yellowish 3-(4,5-dimethyl thiazol-2-yl)-2,5-diphenyl tetrazolium salt (MTT) is a substrate of mitochondrial dehydrogenase enzyme, which, upon removal of the bromide, converts to insoluble purple MTT formazan. Through a combination of patterned papers and the enzymatic reaction with human sperm, we can estimate the motility of human sperm (in order to monitor the quality of human sperm) at home without using a microscope in a clinic. (2) Sperm concentrating device: We compare the time of adsorption onto micro-beads as a model of embryos, and evaluate the required time for fertilization.

Countries

Japan

Contacts

Public ContactKoji Matsuura

Okayama University Cardiovascular Physiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences

kojimatu@md.okayama-u.ac.jp086-251-8610

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026